Catalyst Pharmaceutical Partners, Inc. Announces Commencement of CPP-109 Investigator-Sponsored Study in Patients With Treatment Refractory Tourette's Disorder
Published: Sep 24, 2012
CORAL GABLES, Fla., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that researchers at Mount Sinai School of Medicine in New York have commenced a safety and tolerability trial of vigabatrin in young adults with treatment refractory Tourette's Disorder (TD) to evaluate whether CPP-109 (vigabatrin) can potentially reduce the severity of debilitating tics. The researchers hope that the results from their study of CPP-109 will provide initial evidence of efficacy to support the conduct of a larger clinical trial and FDA approval of CPP-109 for the treatment of refractory Tourette's Disorder.